75686-07-6 Usage
Description
13-cis-Fenretinide, an isomer of all-trans-Fenretinide (F250000), is a synthetic analog of Vitamin A. It possesses unique properties that make it a promising candidate for various applications, particularly in the pharmaceutical and medical industries.
Uses
Used in Pharmaceutical Industry:
13-cis-Fenretinide is used as a therapeutic agent for the treatment of certain types of cancer. It has been found to exhibit anti-cancer properties by targeting cancer cell differentiation and apoptosis, making it a potential option for cancer treatment.
Used in Medical Research:
In the field of medical research, 13-cis-Fenretinide is utilized as a research tool to study the effects of Vitamin A analogs on cellular processes and their potential role in cancer development and progression. This helps in understanding the underlying mechanisms and identifying new therapeutic targets.
Used in Drug Development:
13-cis-Fenretinide serves as a starting point for the development of new drugs with improved efficacy and reduced side effects. Its unique structure and properties allow researchers to modify and optimize its pharmacological profile, leading to the creation of more effective cancer treatments.
Used in Clinical Trials:
As a potential cancer treatment, 13-cis-Fenretinide is involved in various clinical trials to evaluate its safety, efficacy, and optimal dosages for different types of cancer. These trials are crucial in determining the drug's role in cancer therapy and its potential for widespread use in the medical field.
Check Digit Verification of cas no
The CAS Registry Mumber 75686-07-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,6,8 and 6 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 75686-07:
(7*7)+(6*5)+(5*6)+(4*8)+(3*6)+(2*0)+(1*7)=166
166 % 10 = 6
So 75686-07-6 is a valid CAS Registry Number.
InChI:InChI=1/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18-
75686-07-6Relevant articles and documents
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor
Campos-Sandoval, José Angel,Redondo, Clara,Kinsella, Gemma K.,Pal, Akos,Jones, Geraint,Eyre, Gwen S.,Hirst, Simon C.,Findlay, John B. C.
experimental part, p. 4378 - 4387 (2011/09/14)
Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions. A series of retinoid analogues were synthesized and examined for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. A number inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development. Shortening the chain length of the FEN derivative substantially abolished binding to sRBP, indicating that the strength of the interaction lies in the polyene chain region. Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compounds on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.
